Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Availability of the Enhanced Liver Fibrosis (ELF) Test Affects the Rate of Diagnosis of Nonalcoholic Steatohepatitis (NASH) With Fibrosis in Patients Referred to Hepatology

NCT05370053 is registered in ClinicalTrials.gov with University of Kansas Medical Center as lead sponsor.

NCT NCT05370053
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05370053 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Availability of the Enhanced Liver Fibrosis (ELF) Test Affects the Rate of Diagnosis of Nonalcoholic Steatohepatitis (NASH) With Fibrosis in Patients Referred to Hepatology
Lead sponsor
University of Kansas Medical Center
Phase
Not applicable
Overall status
Completed
Start date
September 1, 2020
Completion date
December 1, 2022
Enrollment
450 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

fatty liver, nafld